近日，无锡途深智合人工智能科技有限公司及其子公司上海途深生物科技有限责任公司（以下简称「途深智合」）宣布完成数百万元天使轮融资，本次融资由诚美资本领投。据悉，本轮融资资金主要用于实验室的建设和团队搭建。
成立于2023年的「途深智合」，是一家专注于人工智能蛋白质设计和制造的生物科技企业。该公司致力于利用人工智能技术为合成生物领域开发新产品提供解决方案和新产品。在当前生物科技快速发展的背景下，人工智能在蛋白质设计和优化领域的应用正日益受到关注。
据了解，蛋白质是生命体系中的关键组成部分，其在生物体内的功能和作用至关重要。通过人工智能技术，可以更高效、更准确地进行蛋白质设计和优化，从而为生物科技领域带来更多的创新和发展。
「途深智合」表示，本次融资将用于实验室的建设，包括购置先进的实验设备和招聘优秀的科研人员，以进一步提升公司的研发能力。同时，公司也将加大团队建设力度，吸引更多优秀人才加入，为公司的未来发展打下坚实基础。
作为投资方的诚美资本表示，他们非常看好「途深智合」的发展前景。诚美资本认为，人工智能在生物科技领域的应用具有巨大的市场潜力，而「途深智合」团队在人工智能蛋白质设计和优化方面拥有丰富的经验和专业知识，有望在这个领域取得重要突破。
综上所述，人工智能蛋白质设计与优化公司「途深智合」完成数百万元天使轮融资，标志着我国在人工智能生物科技领域的又一重要进展。随着人工智能技术的不断发展和应用，相信「途深智合」将会在未来为合成生物领域带来更多的创新和发展。
英语如下：
**News Title:** “AI-Powered Biotech Company ‘Tushen Zhihe’ Completes Several Million RMB Seed Financing”
Keywords: Tushen Zhihe, Seed Financing, AI Protein Design.
News Content: # Tushen Zhihe, a Biotech Company Focused on AI Protein Design and Optimization, Completes Several Million RMB Seed Financing
Recently, Wuxi Tushen Zhihe Artificial Intelligence Technology Co., Ltd., and its subsidiary Shanghai Tushen Biotechnology Co., Ltd. (collectively referred to as “Tushen Zhihe”) announced the completion of several million RMB seed financing led by Chengmei Capital. It is understood that the funds raised will primarily be used for the establishment of the laboratory and team building.
Founded in 2023, Tushen Zhihe is a biotech enterprise specializing in AI protein design and manufacturing. The company is dedicated to using artificial intelligence technology to develop new products for the synthetic biology field. Against the backdrop of rapid development in biotechnology, the application of artificial intelligence in protein design and optimization is increasingly garnering attention.
It is known that proteins are key components in life systems, and their functions and roles in living organisms are crucial. By using artificial intelligence technology, protein design and optimization can be conducted more efficiently and accurately, bringing more innovation and development to the biotech field.
Tushen Zhihe stated that the financing will be used to build a laboratory, including the purchase of advanced experimental equipment and the recruitment of outstanding scientific researchers, to further enhance the company’s research and development capabilities. In addition, the company will also strengthen its team building efforts, attracting more outstanding talents to lay a solid foundation for the company’s future development.
As an investor, Chengmei Capital expressed their optimism about Tushen Zhihe’s development prospects. Chengmei Capital believes that the application of artificial intelligence in the biotech field has significant market potential. They consider the Tushen Zhihe team to have rich experience and professional knowledge in AI protein design and optimization, poised for significant breakthroughs in this field.
In summary, Tushen Zhihe, a biotech company focused on AI protein design and optimization, has completed several million RMB in seed financing, marking another significant advancement in China’s AI biotech sector. With the continuous development and application of artificial intelligence technology, Tushen Zhihe is expected to bring more innovation and development to the synthetic biology field in the future.
【来源】https://36kr.com/p/2686282258132355
Views: 1